GlassScriptPhysician profile
Kassia Silva
NPI 1003279316
$43,584.16
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35K · 2021: $1,644 · 2022: $3,509 · 2023: $3,227 · 2024: $51.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Travel and Lodging: $1,378 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.36 |
| Travel and Lodging | $1,377.78 |
| Education | $107.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $20,000.00 | 2020 | |
| Boston Scientific Corporation | $15,760.40 | 2020-2023 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Medtronic, INC. | $3,042.84 | 2021-2023 | Intellis Adaptivestim, Synchromedii |
| Mml US, INC. | $2,514.46 | 2022-2023 | Reactiv8 |
| Abbott Laboratories | $720.51 | 2020-2024 | Proclaim |
| Relievant Medsystems, INC. | $462.46 | 2020-2023 | Intracept |
| Spr Therapeutics, INC | $244.14 | 2022-2023 | Sprint Pns System |
| Abbvie INC. | $183.80 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Painteq LLC | $142.23 | 2022-2023 | Painteq |
| Tersera Therapeutics LLC | $102.08 | 2021-2023 | Prialt |
| Amgen INC. | $53.65 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.15 | 2023-2024 | Relistor |
| Nevro Corp. | $37.28 | 2022-2023 | Senza |
| Biohaven Pharmaceuticals, INC. | $37.22 | 2021 | |
| Lilly USA, LLC | $26.27 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $22.47 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $21.52 | 2023 | Ztlido |
| Depuy Synthes Sales INC. | $20.92 | 2023 | Orthovisc, Monovisc |
| Pfizer INC. | $20.59 | 2023 | |
| Collegium Pharmaceutical, INC. | $20.02 | 2021 | |
| Ibsa Pharma INC. | $19.88 | 2023 | Tirosint, Licart |
| Biogen, INC. | $16.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.36 | 2023 | Quviviq |
| Vertos Medical, INC. | $15.87 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.05 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.41 | 2021 | |
| Nalu Medical, INC. | $10.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassia Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.